8-week sofosbuvir-velpatasvir non-inferior to 12 weeks for HCV

The RESOLVE trial, a multicentre randomised controlled trial in India, compared 8 weeks versus 12 weeks of sofosbuvir-velpatasvir in 880 treatment-naive, non-cirrhotic adults with chronic hepatitis C. The trial reported that the 8-week regimen achieved sustained virological response rates non-inferior to the 12-week regimen in both per-protocol (98.8% vs 99.0%) and intention-to-treat analyses, with no drug-related serious adverse events or discontinuations reported in either group.

Most relevant for: Treatment-naive adults with non-cirrhotic chronic hepatitis C infection being considered for direct-acting antiviral therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.